ENLV Enlivex Therapeutics

Enlivex: After Expedited Review, Israeli Ministry of Health Authorizes Initiation of Phase II Clinical Trial Evaluating Allocetra in COVID-19 Severe and Critical Patients

Enlivex: After Expedited Review, Israeli Ministry of Health Authorizes Initiation of Phase II Clinical Trial Evaluating Allocetra in COVID-19 Severe and Critical Patients
EN
13/10/2020

Underlying

ENLVEnlivex Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Enlivex Therapeutics

 PRESS RELEASE
Free
ENLV Enlivex Therape...

Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap ...

Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra™ Results  Allocetra™ demonstrated statistically significant and clinically meaningful improvements in pain and function in Phase IIa trial in primary osteoarthritis patients   Six-month data expected November 2025; Phase IIb trial initiation planned for Q2 2026 Nes-Ziona, Israel, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Enlivex”), a clinical-stage macrophage reprogramming immunotherapy company, today issued the following update to sh...

September 11, 2025 1 EN
 PRESS RELEASE
Free
ENLV Enlivex Therape...

Enlivex Announces Positive Topline Data From Multi-Country, Randomized...

Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis ENX-CL-05-001 Trial: 3-months topline data -   In the overall modified intention-to-treat (mITT) population, improvements across all efficacy and secondary endpoints, including 24% reduction in knee pain and 26% improvement in knee function, were observed in the AllocetraTM treatment arm vs placebo; moreover, 72% reduction in knee pain and 95% improvement in knee function were observed for age-related primary osteo...

August 18, 2025 1 EN
 PRESS RELEASE
Free
ENLV Enlivex Therape...

Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe...

Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar Webinar to Review Results from Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Allocetra™ in Patients with Moderate to Severe Knee Osteoarthritis Nes-Ziona, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced it will host a  on Monday, August 18, 2025, at 8:00 AM Eastern Time to present and discuss 3-month topline res...

August 14, 2025 1 EN
 PRESS RELEASE
Free
ENLV Enlivex Therape...

Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of P...

Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data Nes-Ziona, Israel, July 28, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that all 134 patients in its Phase II stage of its randomized, controlled, blinded Phase I/II trial of Allocetra™ in patients with moderate to severe knee osteoarthritis, have completed a follow-up period of at least three months, the trial’s primary timepoint for measurement of key endpoints. The data are bein...

July 28, 2025 1 EN
 PRESS RELEASE
Free
ENLV Enlivex Therape...

Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoart...

Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology Ness-Ziona, Israel, June 10, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it will present a poster at the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology, taking place June 11-14, 2025, in Barcelona, Spain. The Company’s presentation will feature data from the ongoing clinical study evaluating Allocetr...

June 10, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch